The crucial role of the AβPP proteolytic/secretory pathway in only the first, pre-symptomatic stage of AD explains why the drugs targeting extracellular AβPP-derived Aβ or its production by the AβPP proteolysis did not and indeed could not have any effect on symptomatic AD patients. This evidence concerns the gene APP and Alzheimer disease.